| アブストラクト | OBJECTIVE: To systematically characterize the post-marketing safety signals of isotretinoin using real-world data from the U.S. FDA Adverse Event Reporting System (FAERS), with independent external validation in the European EudraVigilance (EV) database. METHODS: Adverse event (AE) reports in FAERS from 2004Q1 to 2024Q3 were analyzed. Signal detection was conducted using four complementary disproportionality algorithms: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS). Signals concurrently detected by all four methods were defined as robust. Key findings were subsequently examined in EV as an external reference. RESULTS: Among 50,519 patients contributing 142,160 isotretinoin-associated AE reports, 469 statistically robust signals were identified, spanning 25 system organ classes (SOCs). Signals were most concentrated in psychiatric disorders (75, 15.99%), gastrointestinal disorders (58, 12.37%), and congenital, familial, and genetic disorders (50, 10.66%). The strongest association was observed for inflammatory bowel disease (IBD; ROR = 579.14); however, temporal clustering and reporter-type profiling suggested substantial stimulated reporting, potentially driven by litigation, warranting cautious interpretation. Several high-ranking signals were not described in current product labeling, including nasal vestibulitis, hypertrophic anal papilla, and SAPHO syndrome. Pregnancy-related signals were prominent, with unintended pregnancy showing a strong signal (ROR = 91.39). External validation in EV demonstrated high concordance, supporting the robustness and reproducibility of the findings. CONCLUSIONS: Isotretinoin is associated with a broad spectrum of pharmacovigilance signals, with disproportionate representation of psychiatric, gastrointestinal, and pregnancy-related events. While multiple previously unlabelled signals emerged, their clinical relevance remains to be established. These findings underscore the need for strengthened clinical monitoring, rigorous pregnancy prevention strategies, and careful interpretation of spontaneous reporting data. |
|---|
| 組織名 | Department of Pharmacy, Affiliated Hospital of Southwest Medical University,;Luzhou city, Sichuan Province, China.;Department of Pharmacy, the First People's Hospital of Yibin, YinBin city,;Sichuan Province, China.;Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of;Pharmacy, Sichuan Academy of Medical Sciences, Sichuan Provincial People's;Hospital, Affiliated Hospital of University of Electronic Science and Technology;of China, Chengdu city, Sichuan Province, China. |
|---|
